Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28085418 | 0.91 | CYP3A4 (0.57) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL5475900 | 0.88 | RECQL (0.63) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL27886570 | 0.87 | CYP3A4 (0.60) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL358295 | 0.85 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL760609 | 0.85 | GPR84 (0.47) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL4846583 | 0.84 | CYP3A4 (0.64) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL25236063 | 0.83 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL2440937 | 0.83 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL25236891 | 0.83 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ATMRECQL | |
| SCHEMBL25235809 | 0.83 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ATMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019198923-A1 | MICROSTRUCTURE FOR TRANSCUTANEOUS AND INTRACUTANEOUS DRUG DELIVERY OF CYCLOSPORIN A (CSA) | 가천대학교 산학협력단 | 2019-10-17 | — | — | WO | claimed |
| US-20130158092-A1 | New Oral Formulation | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| US-20120071537-A1 | New Oral Formulation | DE BRUIJN KAREL (FR) | 2012-03-22 | — | — | US | claimed |
| EP-2275090-A2 | Microparticles prepared using an ionic liquid | Novartis AG (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100239524-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | claimed |
| US-7511014-B2 | Cyclosporin galenic forms | NOVARTIS AG (CH) | 2009-03-31 | — | — | US | claimed |
| EP-0787011-B1 | microemulsion preconcentrate comprising a macrolide | NOVARTIS AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20080075773-A1 | New Oral Formulation | DE BRUIJN KAREL | 2008-03-27 | — | — | US | claimed |
| EP-1893179-A2 | RAPIDLY-DISSOLVING PHARMACEUTICAL COMPOSITION FOR INHIBITING OVULATION | Laboratorios Leon Farma, S.A. (ES) | 2008-03-05 | — | — | EP | claimed |
| US-20070042943-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS | 2007-02-22 | — | — | US | claimed |
| US-20050008704-A1 | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | RAY ANUP KUMAR (US) | 2005-01-13 | — | — | US | claimed |
| US-20040167063-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS (CH) | 2004-08-26 | — | — | US | claimed |
| WO-2004052340-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| EP-1035862-B1 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG PHARM CORP (KR) | 2003-07-09 | — | — | EP | claimed |
| US-20030060402-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS (CH) | 2003-03-27 | — | — | US | claimed |
| US-20020013272-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS (CH) | 2002-01-31 | — | — | US | claimed |
| EP-1035862-A2 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG CORP (KR) | 2000-09-20 | — | — | EP | claimed |
| US-6063762-A | CYCLOSPORIN MICROEMULSION WITH OILS, SOLVENTS AND SURFACTANTS | CHONG KUN DANG CORP. (KR) | 2000-05-16 | — | — | US | claimed |
| US-6028067-A | AS IMMUNOSUPPRESSANT | CHONG KUN DANG CORP. (KR) | 2000-02-22 | — | — | US | claimed |
| WO-1999000002-A2 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG CORP. (KR) | 1999-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042943-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CYP3A4 1856/4885TSHR 3515/4885TDP1 1932/4885 |
| US-20040167063-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CYP3A4 1856/4885TSHR 3515/4885TDP1 1932/4885 |
| US-20120071537-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | CYP3A4 585/4885TSHR 4172/4885TDP1 3852/4885 |
| US-20020013272-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CYP3A4 1856/4885TSHR 3515/4885TDP1 1932/4885 |
| US-20100239524-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | FIBP, MIF, CHMP4B | CYP3A4 4551/4885TSHR 3760/4885TDP1 1587/4885 |
| US-20080075773-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | CYP3A4 585/4885TSHR 4172/4885TDP1 3852/4885 |
| US-20130158092-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | CYP3A4 585/4885TSHR 4172/4885TDP1 3852/4885 |
| US-20030060402-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CYP3A4 1856/4885TSHR 3515/4885TDP1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.